|
|
|
Glenmark Life Sciences Ltd.
|
|
|
|
|
Industry : Pharmaceuticals & Drugs |
House : Glenmark |
|
|
|
BSE Code |
543322
|
|
ISIN Demat |
INE03Q201024
|
|
Book Value |
190.35
|
|
|
NSE Code |
GLS
|
|
Dividend Yield(%) |
2.73
|
|
Market Cap(Million) |
100907.25
|
|
|
P/E(X) |
21.43
|
|
EPS(Rs.) |
38.43
|
|
Face Value(Rs.) |
2
|
|
|
|
|
|
|
|
Incorporation Year
|
23-06 2011
|
|
Registered Office
|
Plot No. 170-172,Chandramouli Industrial Estate,Mohol Bazarpeth, Solapur,
Maharashtra-413213 .
|
|
ISINNO
|
INE03Q201024
|
|
Phone
|
02189 234456/234246
|
|
E-mail
|
complianceofficer@glenmarklifesciences.com |
|
URL
|
www.glenmarklifesciences.com |
|
Industry
|
Pharmaceuticals & Drugs
|
|
Chairman
|
|
|
Managing Director
|
Yasir Rawjee
|
|
Company Secretary
|
Rudalf Corriea
|
|
Listing
|
BSE,NSE
|
|
|
|